Showing results (241-250 of 294) with videos related to

Sort By:
Pageof 30
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Science Translational Medicine|October 20, 2021
Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensorsSophie C Cazanave, Andrew D Warren, Maciej Pacula, et al.
Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitisZobair M Younossi, Rohit Loomba, Mary E Rinella, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosisZobair M Younossi, Rohit Loomba, Quentin M Anstee, et al.
Hepatology (Baltimore, Md.)|March 30, 2007
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLDPaul Angulo, Jason M Hui, Giulio Marchesini, et al.
Journal of Inflammation (London, England)|April 1, 2010
Elevated endotoxin levels in non-alcoholic fatty liver diseaseAlison L Harte, Nancy F da Silva, Steven J Creely, et al.
The American Journal of Gastroenterology|May 13, 2015
PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver DiseaseHabeeb Salameh, Evan Raff, Angelika Erwin, et al.
Journal of Hepatology|June 6, 2021
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver diseaseRamy Younes, Gian Paolo Caviglia, Olivier Govaere, et al.
Pageof 30